在中和单克隆抗体治疗后,长期抗SARS-CoV-2抗体轨迹
Elizabeth S Munroe1, Greg A Grandits2, Robert C Hyzy1
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
PloS one
|June 18, 2025
概括
针对COVID-19的中和单克隆抗体 (nMAbs) 并没有抑制长期免疫反应. 与安慰剂相比,接受nMAbs治疗的患者表现出类似的抗核囊抗体水平,这表明内源性幽默免疫力没有受损.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中和单克隆抗体 (nMAbs) 用于COVID-19和其他感染.
- 人们担心nMAbs可能会阻碍免疫系统对SARS-CoV-2的反应,可能会降低长期保护.
研究的目的:
- 研究nMAbs对住院COVID-19患者内源性免疫反应的影响.
- 为了比较接受nMAbs和安慰剂的患者之间的长期抗SARS-CoV-2抗体反应.
主要方法:
- 来自四个ACTIV-3/TICO试验的数据汇总,涉及COVID-19的nMAbs或安慰剂.
- 与28日和90日抗SARS-CoV-2尖端蛋白中和抗核囊反应进行比较.
- 利用线性混合效应模型来分析纵向抗体轨迹.
主要成果:
- 在28天和90天,nMAbs治疗与更高的抗尖峰中和活性有关.
- 在28天和90天,nMAbs和安慰剂组之间的抗核囊反应相似.
- 没有观察到内源性免疫反应 (抗核囊) 的显著差异.
结论:
- 对于住院COVID-19患者的nMAbs治疗没有抑制长期的抗核囊抗体反应.
- 这些发现表明,中和抗体疗法不会损害本种人群内源性幽默性免疫反应.
- 这支持在不损害长期免疫力的情况下继续使用nMAbs治疗病毒感染.
更多相关视频
相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Coronavirus
Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...


